| 1. |
|
|
| 2. |
- Cossarizza, A., et al.
(author)
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
- 2019
-
In: European Journal of Immunology. - : Wiley. - 0014-2980 .- 1521-4141. ; 49:10, s. 1457-1973
-
Journal article (peer-reviewed)abstract
- These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer-reviewed by leading experts in the field, making this an essential research companion.
|
|
| 3. |
|
|
| 4. |
- Cerutti, P. O., et al.
(author)
-
The socioeconomic and environmental impacts of wood energy value chains in Sub-Saharan Africa : A systematic map protocol
- 2015
-
In: Environmental Evidence. - : Springer Science and Business Media LLC. - 2047-2382. ; 4:1
-
Journal article (peer-reviewed)abstract
- Background: The vast majority of households in Sub-Saharan Africa (SSA) depend on wood energy - comprising firewood and charcoal - for their daily energetic needs. Such consumption trends are expected to remain a common feature of SSA's wood energy production and supply chains, at least in the short- to medium-terms. Notwithstanding its importance, wood energy generally has low priority in SSA national policies. However, the use of wood energy is often considered a key driver of unsustainable management and negative environmental consequences in the humid and dry forests. To date, unsystematic assessments of the socio-economic and environmental consequences of wood energy use have underplayed its significance, thus further hampering policy debates. Therefore, a more balanced approach which considers both demand and supply dynamics is needed. This systematic map aims at providing a comprehensive approach to understanding the role and impacts of wood energy across all regions and aspects in SSA. Methods: The objective of this systematic map is to collate evidence from studies of environmental and socio-economic impacts of wood energy value chains, by considering both demand and supply within SSA. The map questions are framed using a Populations, Exposure, Comparators and Outcomes (PECO) approach. We name the supply and demand of wood energy as the "exposure," composed of wood energy production, harvesting, processing, and consumption. The populations of interest include both the actors involved in these activities and the forest sites where these activities occur. The comparator is defined as those cases where the same wood energy activities occur with i) available/accessible alternative energy sources, ii) regulatory frameworks that govern the sector and iii) alternative technologies for efficient use. The outcomes of interest encompass both socioeconomic and environmental impacts that can affect more than the populations named above. For instance, in addition to the direct socioeconomic impacts felt by participants in the wood energy value chain, forest dwellers may experience livelihood changes due to forest degradation caused by external harvesters. Moreover, intensified deforestation in one area may concurrently lead to forest regeneration in another.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Gruber, Günther, et al.
(author)
-
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
- 2005
-
In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 0732-183X. ; 23:28, s. 7089-97
-
Journal article (peer-reviewed)abstract
- PURPOSE: We sought to determine retrospectively whether extracapsular spread (ECS) might identify a subgroup that could benefit from radiotherapy after mastectomy, especially patients with 1 to 3 positive lymph nodes (LN1-3+). PATIENTS AND METHODS: We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil). After a review of all pathology forms, 933 patients (63%) had information on the presence or absence of ECS. ECS was present in 49.5%. The median follow-up was 10 years. RESULTS: In univariate analyses, ECS was associated with worse disease-free survival (DFS) and overall survival (OS). In multivariate analyses adjusting for tumor size, vessel invasion, surgery type, and age group, ECS remained significant (DFS: hazard ratio, 1.61; 95% CI, 1.34 to 1.93; P < .0001; OS: 1.67; 95% CI, 1.34 to 2.08; P < .0001). However, ECS was not significant when the number of positive nodes was added. The locoregional failure rate +/- distant failure (LRF +/- distant failure) within 10 years was estimated at 19% (+/- 2%) without ECS, versus 27% (+/- 2%) with ECS. The difference was statistically significant in univariate analyses, but not after adjusting for the number of positive nodes. No independent effect of ECS on DFS, OS, or LRF could be confirmed within the subgroup of 382 patients with LN1-3+ treated with mastectomy without radiotherapy. CONCLUSION: Our results do not support an independent prognostic value of ECS, nor its use as an indication for irradiation in premenopausal patients with LN1-3+ treated with classical CMF. However, we could not examine whether extensive ECS is of prognostic importance.
|
|
| 9. |
- Kerzeli, Iliana K., et al.
(author)
-
MALT1 inhibition suppresses antigen-specific T cell responses
- 2024
-
In: Cellular Immunology. - : Elsevier. - 0008-8749 .- 1090-2163. ; 397
-
Journal article (peer-reviewed)abstract
- The aim of this study was to assess the potential use of a selective small molecule MALT1 inhibitor in solid tumor treatment as an immunotherapy targeting regulatory T-cells (Tregs). In vitro, MALT1 inhibition suppressed the proteolytic cleavage of the MALT1-substrate HOIL1 and blocked IL-2 secretion in Jurkat cells. It selectively suppressed the proliferation of PBMC-derived Tregs, with no effect on conventional CD4+ T-cells. In vivo, however, no evident anti-tumor effect was achieved by MALT1 inhibition monotherapy or in combination with anti-CTLA4 in the MB49 cancer model. Despite decreased Treg-frequencies in lymph nodes of tumor-bearing animals, intratumoral Treg depletion was not observed. We also showed that MALT1-inhibition caused a reduction of antigen-specific CD8+ T-cells in an adoptive T-cell transfer model. Thus, selective targeting of Tregs would be required to improve the immunotherapeutic effect of MALT1-inhibition. Also, various dosing schedules and combination therapy strategies should be carefully designed and evaluated further.
|
|
| 10. |
- Kerzeli, Iliana Kyriaki, et al.
(author)
-
MALT1 inhibition suppresses T-cell dependent immune surveillance
-
Other publication (other academic/artistic)abstract
- MALT1 supports the development of natural regulatory T cells (Tregs), while protease-dead MALT1 (MALT1-PD) mice develop autoimmunity and an intrinsic capacity to reject syngeneic tumor transplantation. Herein, a small molecule inhibitor targeting MALT1 was developed and evaluated for potential use in Treg inhibition as part of a cancer immunotherapy strategy.In vitro, MALT1 inhibitor treatment inhibited the proteolytic cleavage of the MALT1 substrate HOIL1 in Jurkat cells and blocked IL-2 secretion by immune cells. Moreover, orally administrated MV088428 inhibited anti-CD3 induced IL-2 release in vivo. In vitro MALT1 inhibition selectively suppressed the proliferation of PBMC derived CD25+ FoxP3+ CD4+ T cells, while no direct effect was noted on the proliferation and viability of CD25- CD4+ T cells. In vivo, no evident anti-tumor effect as a monotherapy in the MB49 bladder cancer model was achieved and despite selective decrease of Treg frequencies in lymph nodes of tumor bearing animals, intratumoral Treg depletion was not observed. No synergistic anti-tumor effects were noted when MALT1 inhibitor was combined with anti-PD1 therapy, and concomitant treatment with MALT1 inhibitor abrogated the efficacy of anti-CTLA4 therapy. MALT1 inhibition had no impact on the frequencies of viable NK, lymphocyte and myeloid cells or on proliferation of conventional CD4 and CD8 T cells. However, there was a significant decrease of antigen-specific T cells in vivo upon adoptive T cell transfer and peptide vaccination. Thus, while MALT1 inhibition substantially reduced Treg populations in lymph nodes, but less so in tumors, off-target effects on antigen-experienced T cells along with the lack of impact on tumor Tregs likely abolish the compound’s efficacy. The off-target effect on antigen-experienced T cells could present implications for the use of MALT1 inhibitors for cancer indications where tumor control is likely to be mediated via T cell driven immune surveillance. Thus, dosing length and combination therapy strategies should be carefully designed and evaluated further.
|
|
